The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Scandine     [5-(2-methylaminoethyl)-2- (2...

Synonyms: Ibopamine, Ibopamino, Ibopaminum, Trazyl, CHEMBL307739, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ibopamine


High impact information on Ibopamine

  • Ibopamine stimulates DA-1 and DA-2 receptors and causes peripheral and renal vasodilatation; the drug improves symptoms of heart failure [5].
  • Small transient increments in right atrial and pulmonary capillary wedge pressures occurred 0.5 hr after ingestion of 200 and 300 mg of ibopamine, but these pressures returned to baseline or lower levels within 30 min [6].
  • Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group [7].
  • In patients with early stages of heart failure, digoxin may prevent a progressive deterioration in heart rate variability, whereas ibopamine does not show statistically significant effects [8].
  • Ibopamine was only effective in patients with relatively preserved left ventricular function, as it significantly increased exercise time in this subgroup (for patients with a left ventricular ejection fraction > 0.30; p = 0.018 vs. placebo) [9].

Chemical compound and disease context of Ibopamine


Biological context of Ibopamine


Anatomical context of Ibopamine


Associations of Ibopamine with other chemical compounds

  • We studied 161 patients with mild to moderate chronic heart failure (80% in New York Heart Association functional class II and 20% in class III), who were treated with ibopamine (n = 53), digoxin (n = 55) or placebo (n = 53) for 6 months [9].
  • The effects of oral doses (100, 200, and 400 mg) of a dopamine derivative, ibopamine, on serum prolactin (PRL) and growth hormone (GH) levels were evaluated in hyperprolactinemic patients, some of whom also were acromegalic [22].
  • Serum GH did not rise in nonacromegalic subjects, but it fell after 400 mg ibopamine in the L-dopa-sensitive acromegalic patients [22].
  • These findings indicate that, unlike other dopaminergic agonists, administration of ibopamine results in increased glucose levels without affecting glucagon [23].
  • In addition, new drugs, such as angiotensin II receptor antagonists, beta-adrenoceptor antagonists, ibopamine, Ca(2+) antagonists, neutral endopeptidase inhibitors, vasopressin antagonists, Ca(2+)-sensitizers with cyclic AMP-dependent or -independent mechanisms, and endothelin antagonists, are also being used [24].

Gene context of Ibopamine

  • Effects of ibopamine on serum prolactin and growth hormone levels in hyperprolactinemic and acromegalic subjects [22].
  • In healthy volunteers and patients with heart failure, a single oral dose of ibopamine showed primary vasodilating action (postsynaptic DA1 activity and presynaptic DA2 activity) [16].
  • At week 8, supine (P = 0.076) and erect renin (P = 0.05) were lower with ibopamine treatment [10].
  • The lack of the presumed fall in FF may be the consequence of the expected DA1-induced renal vasodilation, partially reversed by the alpha adrenergic properties of ibopamine for this dose [17].
  • Epinine and dopamine were equipotent and were 10 times more potent than ibopamine as directly acting beta-1 adrenoceptor agonists.(ABSTRACT TRUNCATED AT 250 WORDS)[25]

Analytical, diagnostic and therapeutic context of Ibopamine


  1. Ibopamine and survival in severe congestive heart failure: PRIME II. Girbes, A.R., Zijlstra, J.G. Lancet (1997) [Pubmed]
  2. Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis. Salerno, F., Incerti, P., Badalamenti, S., Lorenzano, E., Graziani, G., Morganti, A., Ghirardi, P. Arch. Intern. Med. (1990) [Pubmed]
  3. Ibopamine-induced reversible leukopenia during treatment for congestive heart failure. Said, S.A., Bucx, J.J., Dankbaar, H., Huizing, G., van Gilst, W.H. Eur. Heart J. (1993) [Pubmed]
  4. Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. Buikema, H., van Gilst, W.H., van Veldhuisen, D.J., de Smet, B.J., Scholtens, E., Lie, K.I., Wesseling, H. Cardiovasc. Res. (1993) [Pubmed]
  5. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Hampton, J.R., van Veldhuisen, D.J., Kleber, F.X., Cowley, A.J., Ardia, A., Block, P., Cortina, A., Cserhalmi, L., Follath, F., Jensen, G., Kayanakis, J., Lie, K.I., Mancia, G., Skene, A.M. Lancet (1997) [Pubmed]
  6. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Rajfer, S.I., Rossen, J.D., Douglas, F.L., Goldberg, L.I., Karrison, T. Circulation (1986) [Pubmed]
  7. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. Brouwer, J., van Veldhuisen, D.J., Man in 't Veld, A.J., Haaksma, J., Dijk, W.A., Visser, K.R., Boomsma, F., Dunselman, P.H. J. Am. Coll. Cardiol. (1996) [Pubmed]
  8. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. Brouwer, J., van Veldhuisen, D.J., Man in 't Veld, A.J., Dunselman, P.H., Boomsma, F., Haaksma, J., Lie, K.I. J. Am. Coll. Cardiol. (1995) [Pubmed]
  9. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). van Veldhuisen, D.J., Man in 't Veld, A.J., Dunselman, P.H., Lok, D.J., Dohmen, H.J., Poortermans, J.C., Withagen, A.J., Pasteuning, W.H., Brouwer, J., Lie, K.I. J. Am. Coll. Cardiol. (1993) [Pubmed]
  10. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Andrews, R., Charlesworth, A., Evans, A., Cowley, A.J. Eur. Heart J. (1997) [Pubmed]
  11. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure. Lieverse, A.G., Girbes, A.R., Van Veldhuisen, D.J., Smit, A.J., Zijlstra, J.G., Meijer, S., Lie, K.I., Reitsma, W.D. Eur. Heart J. (1995) [Pubmed]
  12. Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Henwood, J.M., Todd, P.A. Drugs (1988) [Pubmed]
  13. Effect of ibopamine on aqueous humor production in normotensive humans. McLaren, J.W., Herman, D.C., Brubaker, R.F., Nau, C.B., Wayman, L.L., Ciarniello, M.G., Rosignoli, M.T., Dionisio, P. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  14. Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorimetric detection. Boomsma, F., Alberts, G., van der Hoorn, F.A., Man in 't Veld, A.J., Schalekamp, M.A. J. Chromatogr. (1992) [Pubmed]
  15. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects. López-Sendón, J. Am. J. Med. (1991) [Pubmed]
  16. Clinical pharmacology of ibopamine. Itoh, H. Am. J. Med. (1991) [Pubmed]
  17. Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. Girbes, A.R., Kalisvaart, C.J., Van Veldhuisen, D.J., Tan, E.T., Smit, A.J., Reitsma, W.D., Pasteuning, W.H. Eur. Heart J. (1993) [Pubmed]
  18. Dopaminergic drugs in the management of chronic heart failure. Pouleur, H., Raigoso, J., Rousseau, M.F. Eur. Heart J. (1991) [Pubmed]
  19. Reduced disease in aged rats treated chronically with ibopamine, a catecholaminergic drug. Walker, R.F., Weideman, C.A., Wheeldon, E.B. Neurobiol. Aging (1988) [Pubmed]
  20. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. Van Veldhuisen, D.J., Crijns, H.J., Girbes, A.R., Tobé, T.J., Wiesfeld, A.C., Lie, K.I. Am. J. Cardiol. (1991) [Pubmed]
  21. Medical management of chronic heart failure: inotropic, vasodilator, or inodilator drugs? Lang, R. Am. Heart J. (1990) [Pubmed]
  22. Effects of ibopamine on serum prolactin and growth hormone levels in hyperprolactinemic and acromegalic subjects. Ferrari, C., Barbieri, C., Caldara, R., Rampini, P., Paracchi, A., Boghen, M., Rauhe, W.G. Clin. Pharmacol. Ther. (1983) [Pubmed]
  23. Effect on the endocrine system of a new dopaminergic agent, ibopamine. Soreth, J.T., Dubb, J.W., Allison, N.L., Alexander, F., Boden, G., Stote, R.M. Clin. Pharmacol. Ther. (1987) [Pubmed]
  24. Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment. Marín, J., Marín, E., Gutiérrez-Iñiguez, M.A., Avendaño, C., Rodríguez-Martínez, M.A. Pharmacol. Ther. (2000) [Pubmed]
  25. Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine. Nichols, A.J., Ruffolo, R.R. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  26. Confounding by contraindication in a nationwide cohort study of risk for death in patients taking ibopamine. Feenstra, H., Grobbee, R.E., in't Veld, B.A., Stricker, B.H. Ann. Intern. Med. (2001) [Pubmed]
  27. Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment. Marchini, G., Babighian, S., Tosi, R., Perfetti, S., Bonomi, L. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  28. Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure. Ghirardi, P., Brusoni, B., Mangiavacchi, M., Bianco, L., Col, J., Metra, M., Dei Cas, L. British journal of clinical pharmacology. (1985) [Pubmed]
WikiGenes - Universities